» Articles » PMID: 33257092

The Neurobiology of Binge-eating Disorder Compared with Obesity: Implications for Differential Therapeutics

Overview
Journal Clin Ther
Specialty Pharmacology
Date 2020 Dec 1
PMID 33257092
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Emerging work indicates divergence in the neurobiologies of binge-eating disorder (BED) and obesity despite their frequent co-occurrence. This review highlights specific distinguishing aspects of BED, including elevated impulsivity and compulsivity possibly involving the mesocorticolimbic dopamine system, and discusses implications for differential therapeutics for BED.

Methods: This narrative review describes epidemiologic, clinical, genetic, and preclinical differences between BED and obesity. Subsequently, this review discusses human neuroimaging work reporting differences in executive functioning, reward processing, and emotion reactivity in BED compared with obesity. Finally, on the basis of the neurobiology of BED, this review identifies existing and new therapeutic agents that may be most promising given their specific targets based on putative mechanisms of action relevant specifically to BED.

Findings: BED is characterized by elevated impulsivity and compulsivity compared with obesity, which is reflected in divergent neurobiological characteristics and effective pharmacotherapies. Therapeutic agents that influence both reward and executive function systems may be especially effective for BED.

Implications: Greater attention to impulsivity/compulsivity-related, reward-related, and emotion reactivity-related processes may enhance conceptualization and treatment approaches for patients with BED. Consideration of these distinguishing characteristics and processes could have implications for more targeted pharmacologic treatment research and interventions.

Citing Articles

Exploring the utility of N-acetylcysteine for loss of control eating: protocol of an open-label single-arm pilot study.

Muthmainah M, Sketriene D, Anversa R, Harris E, Griffiths S, Gogos A Pilot Feasibility Stud. 2025; 11(1):19.

PMID: 39972374 PMC: 11837714. DOI: 10.1186/s40814-025-01598-5.


Binge Eating and Obesity Differentially Alter the Mesolimbic Endocannabinoid System in Rats.

Schoukroun F, Herbeaux K, Andry V, Goumon Y, Bourdy R, Befort K Int J Mol Sci. 2025; 26(3).

PMID: 39941025 PMC: 11818181. DOI: 10.3390/ijms26031240.


Psychoneurological Links Contributing to Body Mass Index and Eating Disorder Severity.

Reivan Ortiz G, Elizalde B, Tapia C, Granero R Nutrients. 2025; 17(2).

PMID: 39861426 PMC: 11767959. DOI: 10.3390/nu17020296.


Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial.

Grilo C, Ivezaj V, Tek C, Yurkow S, Wiedemann A, Gueorguieva R Am J Psychiatry. 2024; 182(2):209-218.

PMID: 39659158 PMC: 11786997. DOI: 10.1176/appi.ajp.20230982.


Enhancing the outcomes of bariatric surgery with inhibitory control training, electrical brain stimulation and psychosocial aftercare: a pilot study protocol.

Rosch S, Wunsche L, Thiele C, Reinstaller T, Zahle T, Schag K J Eat Disord. 2024; 12(1):202.

PMID: 39654020 PMC: 11626763. DOI: 10.1186/s40337-024-01160-3.


References
1.
Allison K, Grilo C, Masheb R, Stunkard A . Binge eating disorder and night eating syndrome: a comparative study of disordered eating. J Consult Clin Psychol. 2006; 73(6):1107-15. DOI: 10.1037/0022-006X.73.6.1107. View

2.
McElroy S, Guerdjikova A, Blom T, Crow S, Memisoglu A, Silverman B . A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013; 46(3):239-45. DOI: 10.1002/eat.22114. View

3.
OMalley S, Sinha R, Grilo C, Capone C, Farren C, McKee S . Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res. 2007; 31(4):625-34. DOI: 10.1111/j.1530-0277.2007.00347.x. View

4.
Kaye W, Wagner A, Fudge J, Paulus M . Neurocircuity of eating disorders. Curr Top Behav Neurosci. 2011; 6:37-57. PMC: 5957512. DOI: 10.1007/7854_2010_85. View

5.
Foltin R, Haney M . Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates. Pharmacol Biochem Behav. 2007; 86(4):766-73. PMC: 1940269. DOI: 10.1016/j.pbb.2007.03.004. View